Panuveitis is uncommon in the general population, but it is not the rarest form of uveitis. Depending on the region, it accounts for roughly 29% to 46% of all uveitis cases, making it either the most common or second most common anatomical subtype. Uveitis itself affects an estimated 38 to 370 people per 100,000, so panuveitis represents a meaningful slice of an already uncommon condition.
How Panuveitis Compares to Other Types
Uveitis is classified by where inflammation occurs inside the eye. Anterior uveitis affects the front chamber, intermediate uveitis involves the gel-like middle portion, posterior uveitis targets the retina or the tissue layer behind it, and panuveitis involves all of these areas simultaneously. The Standardization of Uveitis Nomenclature (SUN) criteria define panuveitis as inflammation in the anterior chamber, the vitreous, and the retina or choroid, with no single area clearly dominant.
In many Western countries, anterior uveitis is the most frequently diagnosed form. But large studies from Asia tell a different story. A Japanese systematic review found panuveitis accounted for 45.6% of uveitis cases, followed by anterior uveitis at 37.8%, posterior uveitis at 12.5%, and intermediate uveitis at just 3%. A separate Japanese study from 2011 to 2018 reported similar numbers: 42.8% panuveitis and 37.4% anterior. In Vietnam, panuveitis made up 30% of cases, while data from Pakistan put it at 28.9%. In all of these populations, intermediate uveitis was by far the rarest form, typically under 4%.
These regional differences are driven largely by which underlying diseases are most common in a given population. Where tuberculosis, Vogt-Koyanagi-Harada (VKH) syndrome, and Behçet’s disease are prevalent, panuveitis rates climb because those conditions tend to inflame the entire eye rather than just one section.
What Causes It
Panuveitis has both infectious and non-infectious causes. The most commonly identified triggers include tuberculosis, VKH syndrome, Behçet’s disease, sarcoidosis, sympathetic ophthalmia, and syphilis. A large number of cases remain idiopathic, meaning no underlying cause is found despite thorough testing.
VKH syndrome is one of the more distinctive causes. It is an autoimmune condition in which the immune system attacks pigment-producing cells throughout the body. The hallmark is bilateral panuveitis with fluid-filled detachments under the retina, along with swelling of the optic nerve. Over time, the back of the eye can lose pigment, creating what is called a “sunset glow” fundus. Some patients also develop hearing changes, headaches, or patches of skin and hair depigmentation.
Sympathetic ophthalmia is one of the rarest triggers. It occurs when injury or surgery to one eye sets off an immune response that attacks the other, uninjured eye. The general incidence is around 0.03 per 100,000 people per year. After penetrating eye trauma, the risk ranges from about 0.2% to 1%. After routine eye surgery, the risk drops to roughly 0.01% to 0.04%.
In developing countries, infectious causes like tuberculosis are a more prominent driver. In wealthier nations, autoimmune and idiopathic cases tend to dominate the picture. Sarcoidosis alone causes panuveitis in 6% to 33% of sarcoidosis patients, depending on the study.
The Risk of Vision Loss
Panuveitis carries a higher risk of vision complications than other uveitis subtypes because inflammation spans the entire eye. In a British study of 148 panuveitis patients, 84% experienced reduced vision. Among those, 53% had severe visual impairment (vision of 6/60 or worse on a standard eye chart, roughly equivalent to seeing at 6 meters what a person with normal sight can see at 60). Across the entire study cohort, which included all uveitis types, 22% met criteria for legal blindness at some point during follow-up.
A large insurance-based study in the United States examined patients with non-infectious intermediate, posterior, or panuveitis and found that 66% developed at least one eye complication within five years, compared to 24% of matched controls without uveitis. Specific five-year risks included cataracts (35%), visual disturbance (29%), glaucoma (20%), retinal detachment (11%), and blindness or low vision (5%). The overall risk of any complication was more than five times higher than in the general population.
How It Is Treated
Treatment depends on whether the cause is infectious or non-infectious. Infectious panuveitis requires treating the underlying infection directly, whether that means antibiotics for syphilis or tuberculosis therapy.
For non-infectious cases, oral corticosteroids are the standard first-line treatment, used to rapidly suppress inflammation. When inflammation is severe, short courses of high-dose intravenous steroids may be given for a few days before transitioning to oral medication that is gradually tapered. The goal is to control inflammation while minimizing steroid side effects, since long-term steroid use can itself cause cataracts and glaucoma.
When steroids alone cannot control the disease, or when the dose needed to maintain control is too high to be safe long-term, immunosuppressive medications are added. For cases that do not respond to conventional immunosuppressives, biologic therapies that block specific immune signaling molecules (particularly TNF inhibitors) may be considered. Many patients with panuveitis require some form of long-term immunosuppression to prevent recurrent flares and progressive damage.
Why Early Detection Matters
Because panuveitis involves inflammation throughout the eye, complications can accumulate quickly. Cystoid macular edema (fluid buildup in the central retina) is one of the most common reasons for vision loss. Cataracts, glaucoma, and retinal detachment are all significantly more likely over time compared to the general population. The five-year complication rate of 66% underscores how aggressively panuveitis can affect the eye even with treatment.
Patients with known systemic conditions linked to panuveitis, such as sarcoidosis, Behçet’s disease, or VKH syndrome, benefit from routine eye examinations even when they have no visual symptoms, since inflammation can be present before it is noticeable. For those already diagnosed, consistent follow-up allows treatment adjustments before permanent structural damage occurs.